FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

Video

Challenges for patients diagnosed with metastatic HER2+ breast cancer and recent FDA approved-therapies for the third-line setting are reviewed.

Related Videos
Wesley J. Talcott, MD, MBA
Judy C. Boughey, MD
Francisco J. Esteva, MD, PhD
Stephanie L. Graff, MD
Related Content

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

September 27th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

September 27th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

September 27th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023